Ellen Kurek

Researchers gauged 3 pooled study results to consider the safety and tolerability of marketed valbenazine for TD.

Serum levels of interleukin-7 and C-X-C motif chemokine ligand 10 appeared to provide the most accurate means of identifying large differences in disease risk.

According to the review, understanding the basis for the neurodegeneration of MS is the next big challenge for the treatment of the disease.

Until recently, researchers were able to measure only the total concentrations of alpha and beta isomers instead of quantifying each of the 4 isomers.

A highly effective antipsychotic with no major motor side effects is needed.

Determining optimal dose, full benefits & risks requires long-term clinical use.

Studies show rates of depression and suicidality similar to those for placebo.

Treatment with the new VMAT-2 inhibitors is likely to transform TD management.

Trial patients' total maximal chorea score improved by 2 points in 8 weeks.

After 24 weeks, 96% of study patients had stable or better visual acuity than they did at baseline.

The positive results came from a 3 fixed-dose Phase III trial involving nearly 300 patients.

An Italian team presented its research on the topic at the 2017 International Congress of Parkinson’s Disease & Movement Disorders Conference.

Blinded rating of remotely monitored patients supported the drug’s efficacy.

A deeper look a the sole FDA-approved treatment for Tardive Dyskinesia.

The typical nAMD patient loses lines of vision before being diagnosed.

Reassurance should focus on success rates and low risk of serious problems.

Acute intraocular inflammation was less common for ranibizumab than aflibercept.

Perceived Stress Scale worked well in assessing stress levels of AMD patients.

Review explores reducing corticosteroid use with immunomodulatory therapies.

T. gondii is one of the most common causes of infectious posterior uveitis.

In a new study, stroke occurred in 6.6% of the ranibizumab-treated group, compared with 7.0% of the controls matched by sociodemographic factors and comorbidities and 6.7% of the controls matched by sociodemographic factors only. These differences were not statistically significant.

A Spanish research team found an association between testing positive for antibodies to adalimumab (Humira) and a worse outcome of uveitis, but only in those who tested positive permanently. They also found that this association correlated with undetectable trough levels of Humira.

Monthly Avastin injections and quarterly Ozurdex injections produced equivalent improvements in best-corrected visual acuity after 7 months. However, Ozurdex reduced central subfield thickness nine times more than Avastin did, though it was associated with elevated intraocular pressure.

In an 84-year-old woman with AMD and acute deterioration in vision, the oral antioxidant supplement Resvega led to regression of subretinal fluid and eliminated the need for intravitreal injection of an anti-VEGF agent over the course of 9 months.

Investigators found poor asthma control in obese or overweight patients despite optimal treatment and significantly higher BMI values in those with uncontrolled asthma than in those with partially or totally controlled asthma.

Because of the potentially devastating neurologic consequences of syphilis, this sexually transmitted disease should be considered in all patients who initially appear with uveitis.

A Danish electronic records review found that the need for Eylea or Lucentis injections for wet age-related macular degeneration did not change after cataract surgery. Also, vision improved more when the time from last injection to cataract surgery was shorter than when it was longer.

A retrospective chart review study showed that the location of subfoveal fibrovascular scarring in relation to the retinal pigment epithelium correlated with visual outcome in eyes successfully treated with anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.

Regular users of oral bisphosphonates had a higher risk of developing wet age-related macular degeneration than non-users, according to results of a recent Canadian study, and the longer the use, the greater the increased risk.